TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04459845

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Child Interaction Therapy
Description: Parent-child Interaction therapy (PCIT; Eyberg and Robinson, 1982) s a manualized evidence-based behavioral parent training program that integrates social learning and attachment theories. Parents proceed through two distinct phases: Child-Directed Interaction (CDI) resembles traditional play therapy, and Parent-Directed Interaction (PDI) resembles clinical behavior therapy. During all sessions, the therapist coaches each parent in vivo in their use of the CDI and PDI skills with their child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Parent Psychotherapy
Description: Child-parent psychotherapy (CPP; Lieberman et al., 2005) is a relationship-based treatment that integrates attachment, cognitive-behavioral, social-learning, and psychodynamic theories. CPP focuses on the child-parent relationship as a way to improve the child's adaptive functioning. Various treatment strategies are employed including a focus on safety, affect regulation, the joint construction of a trauma narrative, and engagement in developmentally appropriate activities.
Study: NCT00827190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILS-920
Study: NCT00838357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic = Plerixafor
Description: 240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
Study: NCT01528865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg once a day p.o. for 16 weeks.
Study: NCT03878693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fomepizole
Description: IV 4-MP.
Study: NCT00932516

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: South Beach Diet™ with South Beach Diet™ Products

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: South Beach Diet™

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie restricted diet with South Beach Diet™ Products

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie Restricted Diet
Study: NCT02744976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle recommendations
Description: Standard lifestyle recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle recommendations
Description: Standard lifestyle recommendations
Study: NCT01073579

Intervention type: DRUG
Intervention: Sabril®
Description: Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.~Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily.
Study: NCT03869814

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood Draw
Study: NCT00518518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Staloral 300
Description: Staloral 300
Study: NCT03878693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APAP
Description: Oral APAP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APAP
Description: Oral APAP
Study: NCT01489111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses.
Study: NCT01889095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Description: patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH/Reg
Description: patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
Study: NCT02828891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two-Dimensional Transcranial Doppler
Description: Transcranial Doppler will be used to measure CSF pressure.
Study: NCT02800876

Intervention type: OTHER
Intervention: CT-acquisition
Study: NCT00518518

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01010542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ILV-095 300 mg in a 4 to 1 ratio
Description: Single dose of ILV-095 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ILV-095 300 mg in a 4 to 1 ratio
Description: Single dose of Placebo
Study: NCT03093402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101
Description: Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101
Description: Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101
Description: Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
Study: NCT02033356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block with lidocaine 1%
Description: US-guided adductor canal block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block with lidocaine 1%
Description: US-guided adductor canal block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block with lidocaine 1%
Description: US-guided adductor canal block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block with lidocaine 1%
Description: US-guided adductor canal block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block with lidocaine 1%
Description: US-guided adductor canal block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block with lidocaine 1%
Description: US-guided adductor canal block
Study: NCT02800876

Intervention type: OTHER
Intervention: CT-acquisition

Intervention type: OTHER
Intervention: CT-acquisition

Intervention type: OTHER
Intervention: CT-acquisition
Study: NCT02033356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study: NCT04690166

Intervention type: OTHER
Intervention: The speech records related to the reading document
Description: The document consists bit, bet, but words and Diyet passage. Volunteers will read the document in front of the microphone and also the speech will recorded by a computer.

Intervention type: OTHER
Intervention: The speech records related to the reading document
Description: The document consists bit, bet, but words and Diyet passage. Volunteers will read the document in front of the microphone and also the speech will recorded by a computer.
Study: NCT00738621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant, Dexamethasone, Ondansetron
Description: Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aprepitant, Dexamethasone, Placebo
Description: Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time
Study: NCT00851968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pringle's Maneuver
Description: The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
Study: NCT02033356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study: NCT04497181

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Coil embolization surgery
Description: Embolization of aneurysms with various coils system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coil embolization surgery
Description: Embolization of aneurysms with various coils system
Study: NCT01413581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBSSL (recombinant human bile-salt-stimulated lipase)
Description: rhBSSL added to infant formula/pasteurized breast milk during a 4 week treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
Study: NCT00408070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: cycle 2 (6 cycles re-evaluated and follow up)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: cycle #1 and continuous through entire regimen; treated every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: cycle #1 and continuous through entire regimen; treated every 3 weeks
Study: NCT01281501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 10 ml of 0.9% sodium chloride solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 80 mg of intravenous pantoprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral antacid
Description: 30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antacid
Description: 30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine butylbromide
Description: 20 mg of intravenous hyoscine butylbromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Description: 20 mg of intravenous hyoscine butylbromide
Study: NCT03786965

Intervention type: OTHER
Group type: OTHER
Intervention: On-pump CABG
Description: On-pump CABG

Intervention type: OTHER
Group type: OTHER
Intervention: Off-pump CABG
Description: Off-pump CABG

Intervention type: OTHER
Group type: OTHER
Intervention: Pump-assisted CABG
Description: Pump-assisted CABG

Intervention type: OTHER
Group type: OTHER
Intervention: Valve Repair Procedure without CABG.
Description: Valve Repair Procedure without CABG (open heart procedure).

Intervention type: OTHER
Group type: OTHER
Intervention: Valve Repair Procedure with CABG.
Description: Valve Repair Procedure with CABG (open heart procedure).
Study: NCT00807196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 250mg/m2 day -21 and day -14 of preparative regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan (Zevalin)
Description: 0.4 mCi/kg IV on day -14 of preparative regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
Study: NCT03336970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NaOCl

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHX
Study: NCT00807196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non myeloablative allogeneic stem cell transplantation
Description: Blood stem cell infusion on day 0
Study: NCT02033356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study: NCT01624584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Description: six sessions of child anxiety treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Treatment
Description: six sessions of treatment consistent with current practice
Study: NCT01147497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
Study: NCT04142645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OptiMEDs
Description: The OptiMEDs intervention is a multi-faceted intervention combining:~1. an ICT platform:~   * automatic and secure capture of individual prescribing information from the electronic medication administration records in the nursing home~  * a tool for structured nurse observations of side effects, derived from the existing Pharmanurse application (20) (used to list potential medication side effects, based on the individual medication chart of the nursing home residents) to support monitoring of medication safety by nurses.~  * an electronic decision support tool for the appraisal of potentially inappropriate medication (explicit criteria of misuse and underused of medication, based on existing lists of explicit criteria (PIMs)), use of medication with anticholinergic properties and medication inappropriate in view of the limited life expectancy.~2. a multidisciplinary medication review with the input of GPs, trained community-pharmacists and nurses.
Study: NCT03336970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Study: NCT03965585

Intervention type: PROCEDURE
Intervention: in-office hysteroscopy
Description: in-office hysteroscopy with miniaturized instruments

Intervention type: PROCEDURE
Intervention: in-office hysteroscopy
Description: in-office hysteroscopy with miniaturized instruments

Intervention type: PROCEDURE
Intervention: in-office hysteroscopy
Description: in-office hysteroscopy with miniaturized instruments
Study: NCT04189523

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC Pain Management
Description: Study subjects will be compared to historical controls selected for same age +/- 5yrs, gender, fracture type who meet the inclusion criteria and do not have historical documentation of one of the exclusion criteria. Controls will be identified by the ICD-10 injury codes selected for use in this study. Clinical course and pain management data will be collected through the EMR only.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early US Guided Nerve Block Administration
Description: US-Guided regional anesthesia (fascia illiaca compartment block or brachial plexus block)
Study: NCT04130087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline Hydrochloride 10 MG
Description: Single 10mg tablet of Selegiline Hydrochloride
Study: NCT00851968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemihepatic vascular Clamping
Description: The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal vein occlusion
Description: The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
Study: NCT02603965

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 TP3805
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo Cu-64-TP3805 PET(Positron Emission Tomography)/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Cu-64-TP3805 PET/CT (Computed Tomography)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02051699

Intervention type: PROCEDURE
Intervention: radiographic of standing knee
Description: the patients stand on their one leg with pillar support and both-leg then shoot the x-ray beam to their knee

Intervention type: PROCEDURE
Intervention: radiographic of standing knee
Description: the patients stand on their one leg with pillar support and both-leg then shoot the x-ray beam to their knee
Study: NCT03943537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Insulin
Description: 40 units Novolin R administered intranasally using ViaNase device.
Study: NCT02373371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metvix®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix®

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy Blue light
Description: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy Daylight
Description: Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug
Study: NCT03707028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution administered intravenously
Study: NCT03676101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent HPV Recombinant Vaccine
Description: Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
Study: NCT03395119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).
Study: NCT02347631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye
Description: Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the trial. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this experimental arm, Alcon Dailies Total 1 lenses will be worn first.
Study: NCT01936194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA+EPA

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High Olive Oil
Study: NCT02347631

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.
Description: Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the study. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this active comparator arm, Acuvue TruEye lenses will be worn first.
Study: NCT01219842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INVASIVE (INV) treatment
Description: Modern endovascular and/or open revascularisation according to the TASC II recommendations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment (BMT)
Description: Antiplatelet therapy, cilostazol and non-supervised exercise training. Smoking cessation support. Lipid-lowering therapy, diabetes and hypertension treated according to current national guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment (BMT)
Description: Antiplatelet therapy, cilostazol and non-supervised exercise training. Smoking cessation support. Lipid-lowering therapy, diabetes and hypertension treated according to current national guidelines.
Study: NCT00948740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D (ergocalciferol)
Description: The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
Study: NCT00848744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
Study: NCT04874857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L.
Description: Massage application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby oil
Description: Massage application
Study: NCT03846245

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04130087

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Placebo Tablet, identical appearance to experimental tablet.
Study: NCT00410488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron - Single Dose
Description: 0.25 mg by vein for 1 dose (day 0).
Study: NCT03792048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Compressive Anastomosis
Description: A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy